College Students Can Help People With Rare Medical Conditions by Donating Plasma at a Nearby Center
Donors are compensated for their time and can give plasma twice a week.
King of Prussia, PA — 18 October 2012
Each year thousands of people in the United States who suffer with rare and serious medical disorders receive lifesaving or life-enhancing therapies derived from human plasma. It takes a large number of plasma donations to create enough therapy for just one patient for an entire year. Yet, only a small number of people who are eligible to donate plasma do so.
CSL Behring researches, develops and manufactures plasma-derived and recombinant therapies for the treatment of rare medical conditions such as bleeding disorders and immune deficiencies. The company’s subsidiary,
CSL Plasma, operates one of the largest plasma collection networks in the world to help ensure there is an adequate supply of plasma to meet the needs of people with rare diseases.
Randy Furby, CSL Plasma’s senior vice president and general manager, says there is a strong, worldwide need for plasma, without which essential therapies for treating rare and serious diseases could not be made. “We value our donors’ commitment to providing the plasma that helps save and improve so many lives. Donating plasma is a safe process that is regulated by the U.S. Food & Drug Administration.”
Eligible donors are compensated for their time and may donate plasma up to twice a week. A donor must be at least 18 years of age and weigh at least 110 pounds. Students interested in becoming plasma donors can use the CSL Plasma
collection center locator (http://www.cslplasma.com/plasma-donation-locations) to find a nearby location.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of
CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit
Manager, Corporate Communications